The scientific challenge of hepatitis C.
Cohen
J
J
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004534:Egypt / Q000453:epidemiology; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000453:epidemiology / Q000628:therapy / Q000635:transmission / Q000821:virology; D019698:Hepatitis C, Chronic; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D010330:Patents as Topic; D011994:Recombinant Proteins; D012093:Replicon; D012254:Ribavirin / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines; D014776:Virus Cultivation
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014761:Viral Hepatitis Vaccines; D012254:Ribavirin